CEO & CTO
Researcher, Stéphane ROCHE holds a PhD in Biological and Medical Engineering and is a former University Hospital Assistant of the Grenoble Hospitals. Stéphane ROCHE also holds a Habilitation to Supervise Research. He has worked in the hospitals of Grenoble, Montpellier and Marseille. He has an important background in medical genetics, medical biochemistry and innovative therapies (ORCID, HAL).
QSMetric Potential Indications -Haemochromatosis
QSMetric Potential Indications – Haemochromatosis Discover a potential indication of QSMetric™…
QSMetric Potential Indications – Neurodegeneration with brain iron accumulation
QSMetric Potential Indications – Neurodegeneration with brain iron accumulation Discover a pot…
QSMetric Potential Indications – Huntington disease
QSMetric Potential Indications – Huntington disease Discover a potential indication of QSMetri…
QSMetric Potential Indications – Traumatic brain injury
QSMetric Potential Indications – Traumatic brain injury Discover a potential indication of QSM…
QSMetric Potential Indications – Multiple sclerosis
QSMetric Potential Indications – Multiple sclerosis Discover a potential indication of QSMetri…
QSMetric Potential Indications – Vascular dementia
QSMetric Potential Indications – Vascular dementia Discover a potential indication of QSMetric…
QSMetric Potential Indications – Parkinson disease
QSMetric Potential Indications – Parkinson disease Discover a potential indication of QSMetric…
QSMetric Potential Indications – Alzheimer’s and related diseases
QSMetric Potential Indications – Alzheimer’s and related diseases Discover a potential i…
![QSMetric Potential Indications – [Context] Iron, iron accumulation and ferroptosis](https://www.ventio.net/wp-content/uploads/2024/07/Fer-accumulation-de-fer-et-ferroptose-Ventio-1-1.jpg)
QSMetric Potential Indications – [Context] Iron, iron accumulation and ferroptosis
QSMetric Potential Indications [Context] Iron, iron accumulation and ferroptosis Dr ROCHE Stéphane B…
Stephane Roche becomes CEO of Ventio
Stephane Roche becomes CEO of Ventio Technical Director for the past 2 years, Dr Stephane Roche took…
SFRMBM 2023
Miguel Guevara1, Davy Cam4, Jacques Badagbon4, Stéphane Roche4, Michel Bottlaender3, Yann Cointepas1…
QMRLucca 2022
QSM4SENIOR: Quantitative susceptibility mapping in the aging of the healthy brain. Miguel Guevara1,2…
APP Ab38 Ab40 in FTD
Decreased sAβPPβ, Aβ38, and Aβ40 Cerebrospinal Fluid Levels in Frontotemporal Dementia Gabelle, Audr…
sAPP & Abeta in CSF
Correlations between soluble alpha/beta forms of amyloid precursor protein and Abeta38, 40 and 42 in…
Preanalytical guidelines
Preanalytical guidelines for clinical proteomics investigation of biological fluids S Lehmann, S. Ro…
Biomarkers in CSF
Les marqueurs biologiques protéiques du liquide céphalorachidien : caractéristiques et implications …
Autoantibody in CSF
Auto-antibody profiling on high-density protein microarrays for biomarker discovery in the cerebrosp…
Clinical proteomics in CSF
Clinical proteomics of the cerebrospinal fluid: Towards the discovery of new biomarkers Stéphane Roc…